Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry

Biomedical Chromatography

Volumn 16, Issue 4, 2002, Pages 267-273

  Gao, Weihua ^a   Kishida, Tomoyuki ^a   Kimura, Keisuke ^a   Kageyama, Michiharu ^a   Sumi, Masaki ^a   Yoshikawa, Yukako ^a   Shibata, Nobuhito ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATMOSPHERIC IONIZATION; ATMOSPHERIC PRESSURE; BODY FLUIDS; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; PATIENT MONITORING; PATIENT TREATMENT; RATS;

ANALYTES; BIOLOGICAL SAMPLES; DIALYSATES; HIV-PROTEASE INHIBITORS; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; PROTEASE INHIBITOR; RAT LIVERS; RAT PLASMA; SIMULTANEOUS DETERMINATIONS; SPECTROMETRIC METHODS;

MASS SPECTROMETRY;

ACETIC ACID; ACETONITRILE; AMPRENAVIR; ETHER; INDINAVIR; NELFINAVIR; POTASSIUM DIHYDROGEN PHOSPHATE; PROTEINASE INHIBITOR; SAQUINAVIR;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; ARTICLE; ATMOSPHERIC PRESSURE; CONTROLLED STUDY; DIALYSATE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG LIVER LEVEL; DRUG MONITORING; EXTRACTION; FLOW RATE; IONIZATION; MASS SPECTROMETRY; MICRODIALYSIS; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SAMPLE; SENSITIVITY AND SPECIFICITY; STANDARD;

EID: 0036099692     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.134     Document Type: Article

References (20)

1. Protease inhibitors in patients with HIV disease
2. Determination of indinavir, an HIV -protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography
3. High-perfoumance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nerfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase after liquid-liquid extraction
4. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor
5. Rapid quantitation of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection
6. Simultaneous determination of ritonavir and saqinavir, two human immunodeficiency virus protease inhibitor, in human serum by high-performance liquid chromatography
7. The effect of plasma drug concentrations on HIV clearance rate during quadruple drug therapy
8. High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva
9. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
10. An LC-MS-MS method for the determination of indinavir, and HIV-1 protease inhibitor, in human plasma
11. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
12. Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography
13. Simultaneous determination of the five HIV-protease inhibitors: Amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography
14. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography
15. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
16. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: Study on combinations of two kinds of HIV-1 protease inhibitors
17. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy
18. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
19. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma
20. Development and evaluation of noncompartmental pharmacokinetic analysis program "WinHARMONY" using Visual BASIC language having a function of automatic recognition of terminal elimination phase of plasma drug profile